GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RetinalGenix Technologies RTGN · USD

Health Care · US listing · 🇺🇸 United States

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About RetinalGenix Technologies

From its filings with the US Securities and Exchange Commission

SEC filings

RetinalGenix Technologies is based in Petaluma, California and is incorporated in Delaware. Its shares trade on OTC under the ticker RTGN. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported a net loss of $2.4m. At that date it held total assets of $21,041 and shareholders' equity of −$2.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
7 Jan 2022
Head office
1450 NORTH MCDOWELL BOULEVARD, PETALUMA, CA, 94954
Incorporated in
DE
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Jerry KatzmanPresident, Chief Executive Officer, Interim Chief Financial Officer, Director, since 2018$1.3m
  • Dr. Dessislava BonevaIndependent Director$106,456
  • Dr. Herbert GouldIndependent Director$372,596
  • Dr. Vinay MehindruIndependent Director$159,684

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • RetinalGenix Technologies Inc focuses on ocular disorder treatments with Retinal Imaging Screening Device and RetinalCam.
  • RetinalCam offers 24/7 physician alert system for real-time communication in home monitoring.
  • Retinal Imaging Screening Device provides 200-degree field of view without pupil dilation for high-risk patients.

Weaknesses

  • RetinalGenix has 0 full-time employees despite being a medical device company.
  • The company went public on 7 January 2022 with no full-time staff.
  • RetinalGenix operates in Petaluma, California with no mention of other locations.

Opportunities

  • RetinalGenix can expand RetinalCam usage in primary care centers and telehealth centers.
  • RetinalGenix may grow through diabetic retinopathy and maculopathy treatment markets.
  • RetinalGenix's technology can be adopted in nursing homes for vision loss monitoring.

Threats

  • RetinalGenix faces competition from other medical device companies in Health Care sector.
  • RetinalGenix's lack of full-time employees may hinder product development.
  • RetinalGenix's IPO on 7 January 2022 could face market volatility.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.